Proposed experiment from debate on Perivascular spaces and glymphatic clearance failure in AD

🧫 Experiment Protocol FalsificationNeurodegenerationPDGFRcell_lineproposed

# Proposed experiment from debate on Perivascular spaces and glymphatic clearance failure in AD ## Background and Rationale This experiment examines the role of PDGFR-β signaling in perivascular space dynamics and its impact on glymphatic clearance failure in Alzheimer's disease using advanced imaging approaches. Platelet-derived growth factor receptor-β (PDGFR-β) is expressed by pericytes and plays a crucial role in blood-brain barrier integrity and perivascular space maintenance. Dysfunction of PDGFR-β signaling has been implicated in cerebral amyloid angiopathy and impaired protein clearance from the brain. The experimental design utilizes two-photon microscopy in cell culture models to measure real-time changes in perivascular space architecture during selective PDGFR-β pathway activation or inhibition. Primary brain pericyte cultures will be established and treated with specific PDGFR-β ligands (PDGF-BB) or antagonists (imatinib, sunitinib) while monitoring cellular morphological changes and barrier function using fluorescent tracers. The study will assess how PDGFR-β modulation affects pericyte contractility, vessel diameter, and paracellular permeability - key parameters that influence perivascular fluid flow. Advanced live-cell imaging will capture dynamic changes in pericyte-endothelial interactions and their impact on model blood-brain barrier integrity. This research addresses fundamental questions about how pericyte dysfunction contributes to glymphatic failure and whether targeting PDGFR-β represents a therapeutic opportunity for enhancing brain clearance mechanisms. This experiment directly tests predictions arising from the following hypotheses: - **Pericyte Contractility Reset via Selective PDGFR-β Agonism** - **Retinal Vascular Microcirculation Rescue** - **Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulation** - **SASP-Driven Aquaporin-4 Dysregulation** - **Aquaporin-4 Polarization Rescue** ## Experimental Protocol **Phase 1: Cell Culture Preparation (Days 1-7)** • Establish primary human brain pericyte cultures (n=6 cultures per condition) from commercially available sources • Seed cells at 2×10^4 cells/cm² in PDL-coated imaging dishes • Maintain in pericyte medium (ScienCell) with 2% FBS for 5-7 days until confluence • Transfect with fluorescent markers (mCherry-α-SMA for pericyte identification) • Prepare co-culture systems with human cerebral microvascular endothelial cells (HCMEC/D3) at 1:2 pericyte:endothelial ratio **Phase 2: PDGFR-β Pathway Modulation (Days 8-10)** • Design and validate biased agonists targeting PI3K (compound A, 10-100 nM) vs MAPK (compound B, 10-100 nM) downstream of PDGFR-β • Treat cultures with: vehicle control, PDGF-BB (10 ng/ml), PI3K-biased agonist, MAPK-biased agonist, combination treatments • Perform dose-response curves (0.1-1000 nM) for each compound • Validate pathway selectivity via Western blot for p-AKT (PI3K) and p-ERK1/2 (MAPK) at 15min, 1h, 4h, 24h **Phase 3: Two-Photon Microscopy Analysis (Days 11-14)** • Establish artificial perivascular space model using microfluidic devices with 20-50 μm channels • Load fluorescent dextran tracers (3kDa FITC-dextran, 70kDa Texas Red-dextran) at physiological concentrations (2mg/ml) • Perform live two-photon imaging at 780nm excitation with 5-minute intervals for 2 hours • Measure: tracer velocity, channel diameter changes, pericyte contractility (α-SMA intensity), flow patterns • Quantify perivascular space dynamics using custom ImageJ macros **Phase 4: Proteomics Profiling (Days 12-16)** • Harvest cell lysates at 1h, 4h, 24h post-treatment (n=4 biological replicates per condition) • Perform TMT-based quantitative proteomics (Thermo Q Exactive HF-X) • Focus on PI3K/AKT and MAPK/ERK pathway components plus downstream effectors • Validate key targets via targeted Western blotting and qRT-PCR • Analyze pathway crosstalk using bioinformatics tools (STRING, Ingenuity) **Phase 5: Functional Validation (Days 17-21)** • Assess pericyte contractile function via collagen gel contraction assays • Measure barrier function using transendothelial electrical resistance (TEER) • Evaluate amyloid-β clearance capacity using fluorescent Aβ42 peptides (1 μM) • Perform ATP/lactate measurements for metabolic assessment • Statistical analysis using two-way ANOVA with Tukey post-hoc testing ## Expected Outcomes 1. **Selective pathway activation**: PI3K-biased agonist will increase p-AKT levels 3-5 fold while maintaining baseline p-ERK1/2, with inverse pattern for MAPK-biased agonist (p<0.001, effect size >0.8) 2. **Differential perivascular dynamics**: PI3K activation will increase perivascular space diameter by 15-25% and tracer clearance velocity by 20-30%, while MAPK activation will decrease both parameters by 10-20% (p<0.01) 3. **Distinct proteomic signatures**: >200 differentially expressed proteins between PI3K vs MAPK conditions, with pathway-specific enrichment scores >2.0 for respective signaling cascades 4. **Functional divergence**: PI3K activation will enhance barrier function (TEER increase >20%) and Aβ clearance (>30% improvement), while MAPK activation will impair both functions (>15% decrease, p<0.05) 5. **Contractility differences**: MAPK-biased activation will increase pericyte contractile force by 40-60% in gel contraction assays, while PI3K bias will reduce contractility by 20-30% compared to controls 6. **Metabolic alterations**: PI3K activation will increase ATP production by 25-40% and reduce lactate by 15-25%, indicating enhanced oxidative metabolism (p<0.01) ## Success Criteria • **Pathway selectivity validation**: Achieve >5-fold selective activation of target pathway with <1.5-fold cross-activation of alternative pathway (p<0.001) • **Reproducible imaging data**: Obtain quantifiable two-photon microscopy data from minimum 80% of samples with coefficient of variation <15% for tracer measurements • **Proteomics coverage**: Identify and quantify >5000 proteins with >70% overlap between biological replicates and FDR <0.05 for differential expression analysis • **Functional readout consistency**: Achieve statistical significance (p<0.05) for primary endpoints in >75% of functional assays with effect sizes >0.6 • **Sample size adequacy**: Complete experiments with minimum n=6 biological replicates per condition achieving power >0.8 for detecting 20% differences between groups • **Technical validation**: Confirm key proteomic findings via orthogonal methods (Western blot, qPCR) with >80% concordance and correlation coefficient r>0.7

Source: debate_extraction

🧫 Experiment Extras

📊 Evidence Profile

0 supporting 0 contradicting 0 neutral

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found